REGENERON PHARMACEUTIC

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

16 Dec 2024 08:45:56 By NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

13 Dec 2024 08:46:56 By NetDania Notify

Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma

09 Dec 2024 16:45:23 By Nasdaq GlobeNewswire

Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab

07 Dec 2024 18:00:31 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

21 Nov 2024 09:19:05 By NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

20 Nov 2024 08:58:38 By NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

19 Nov 2024 09:06:22 By NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

18 Nov 2024 08:45:40 By NetDania Notify

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

15 Nov 2024 08:45:06 By NetDania Notify

Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)

14 Nov 2024 23:59:51 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

14 Nov 2024 14:47:28 By NetDania Notify

Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH

13 Nov 2024 06:00:25 By Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

11 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis

06 Nov 2024 00:00:00 By Nasdaq GlobeNewswire

Regeneron Reports Third Quarter 2024 Financial and Operating Results

31 Oct 2024 05:30:01 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI

24 Oct 2024 07:00:04 By Nasdaq GlobeNewswire

Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema

18 Oct 2024 16:05:00 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

27 Sep 2024 08:35:08 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)

27 Sep 2024 06:00:04 By Nasdaq GlobeNewswire

Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024

26 Sep 2024 15:05:00 By Nasdaq GlobeNewswire